Canada Diabetes Market Report and Forecast 2025-2034
Description
The Canada diabetes market was valued at USD 4.52 Billion in 2024, driven by the increasing prevalence of the disease and the rising initiatives to improve diabetes management in the region. The market is expected to grow at a CAGR of 8.46% during the forecast period of 2025-2034, with the value likely to rise from USD 4.91 Billion in 2025 to USD 10.18 Billion by 2034.
Canada Diabetes Market Overview
Diabetes is a chronic disease characterized by the inability of the body to produce sufficient insulin or when the body cannot respond to the effects of insulin effectively, leading to high blood glucose levels. Type 2 diabetes is the most common type of diabetes where the body doesn’t make enough insulin or shows insulin resistance.
Canada Diabetes Market Growth Drivers
Rising Diabetes Cases to Drive Market Expansion
The growing prevalence of diabetes, fuelled by sedentary lifestyles and ageing populations, coupled with the high burden of diabetes-related complications, are key drivers shaping Canada’s diabetes market. A national analysis in 2024 reported 5.8 million Canadians living with diabetes, a figure expected to rise to over 7.3 million by 2034, representing 16% of the population. Additionally, diabetes contributes significantly to cardiovascular disease, kidney failure, and amputations. This alarming trend will amplify the demand for advanced diagnostic tools, innovative therapies, and public health initiatives, accelerating market growth throughout the forecast period.
Government Healthcare Initiatives to Boost Canada Diabetes Market Development
Expanding access to diabetes care through government support is a critical driver for market development. In February 2024, Canada introduced Bill C-64, the Pharmacare Act, covering diabetes medications and devices. Concurrently, the government announced a Device Fund to subsidise essential supplies, including insulin pumps and glucose monitoring devices. A USD 1 million grant was allocated in June 2023 to Diabetes Canada which further supports the strategic implementation of the national diabetes framework. These initiatives will enhance accessibility and affordability of care, driving the adoption of advanced treatment options and significantly contributing to market growth in the coming years.
Adoption of Innovative Therapies to Meet the Increasing Canada Diabetes Market Demand
Rising demand for convenient and patient-friendly therapies continues to drive innovation in diabetes treatment. In June 2024, Novo Nordisk introduced Awiqli® (insulin icodec), the world’s first once-weekly basal insulin, in Canada following Health Canada approval in March 2024. This groundbreaking therapy, designed to improve glycaemic control with reduced injection frequency, addresses adherence challenges in diabetes management. With Canada leading the global launch of Awiqli®, the treatment is expected to revolutionise insulin therapy standards. Its adoption will boost patient outcomes, foster technological advancements, and position Canada as a leader in diabetes care, driving significant market growth.
Canada Diabetes Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Prevalence of Type 2 Diabetes Fuels Market Development
Type 2 diabetes prevalence in Canada is increasing due to sedentary lifestyles, ageing populations, and unhealthy dietary patterns. As estimated by Diabetes Canada, the prevalence of diagnosed type I and type II diabetes is likely to increase by nearly 32% during 2024-2034. This surge is boosting demand for innovative treatment options, including combination therapies and novel drug classes. Efforts by public health organisations to enhance diabetes awareness and screening are contributing to early diagnoses and treatment adoption. Additionally, pharmaceutical companies are collaborating with healthcare providers to address gaps in care. This trend signifies robust market development as stakeholders focus on mitigating the disease burden and improving patient quality of life.
Growing Adoption of Digital Health Tools in Diabetes Management to Meet Increasing Canada Diabetes Market Demand
Digital health technologies, including mobile apps, continuous glucose monitoring (CGM) systems, and telemedicine, are becoming integral in diabetes care across Canada. These tools empower patients to monitor blood sugar levels in real-time and enable healthcare providers to offer personalised treatment plans remotely. With rising smartphone penetration and improved healthcare infrastructure, the market is witnessing increased investments in digital solutions. This trend highlights a shift towards technology-driven care, driven by patient demand for convenience and accuracy, alongside healthcare professionals' focus on enhanced outcomes.
Expanding Portfolio of Advanced Insulin Delivery Systems
The Canadian diabetes market is experiencing significant advancements in insulin delivery systems, including wearable insulin pumps and smart pens. These innovations improve patient compliance and ensure precise dosage administration. The growing awareness of diabetes complications and government efforts to subsidise innovative treatment devices are driving market growth. Manufacturers are also focusing on integrating AI and connectivity features to offer data-driven solutions. This trend underlines the evolving focus on convenience and efficiency in diabetes management, making insulin delivery more accessible and effective for patients across Canada.
Surge in Demand for Personalised Diabetes Treatments to Boost Canada Diabetes Market Value
The market is witnessing increased demand for personalised therapies tailored to individual needs. Advances in genetic research, artificial intelligence, and patient data analysis are enabling customised treatment plans, including specific drug combinations and lifestyle recommendations. This approach enhances treatment effectiveness and minimises side effects, making it a preferred choice for healthcare providers and patients alike. Pharmaceutical companies are investing in precision medicine to meet this growing demand. The shift towards personalised care signifies a transformative trend, reflecting patient-centric innovation and improved healthcare outcomes in diabetes management across Canada.
Canada Diabetes Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Diabetes Type
Type II Diabetes to Lead the Diabetes Type Segment
Type II diabetes is expected a large market share based on diabetes type, driven by its growing prevalence due to sedentary lifestyles, unhealthy diets, and an ageing population. Its management requires a wide range of treatments, from oral medications to insulin therapies, creating substantial demand. Increased public awareness, early diagnosis programmes, and government healthcare initiatives further fuel growth. As per the analysis by Expert Market Research, the type 2 diabetes market is expected to grow at a CAGR of 8.4% during the forecast period of 2025-2034. Innovations in combination therapies and personalised treatments are poised to expand the segment's dominance in the forecast period, ensuring sustained market growth and improved patient outcomes.
Market Share Based on Drugs to Witness Substantial Growth in the Canada Diabetes Market
The oral anti-diabetic drugs segment is predicted to lead the market due to their convenience, cost-effectiveness, and extensive use in managing type 2 diabetes. Among these, DPP-4 inhibitors and SGLT2 inhibitors are experiencing significant growth due to their dual benefits in glucose control and cardiovascular health. Rising healthcare awareness and a shift towards minimally invasive options are market drivers. With continuous advancements in oral drug formulations and increasing adoption, this segment is expected to maintain its leadership and support future market expansion.
Canada Diabetes Market Share Based on Route of Administration to Hold a Significant Value
Subcutaneous administration leads the diabetes market in Canada due to its critical role in delivering insulin and non-insulin injectables like GLP-1 receptor agonists. Its efficiency in ensuring precise drug delivery and bioavailability makes it a preferred choice for patients and healthcare providers. Technological innovations in auto-injectors and insulin pumps further enhance its appeal. As personalised treatments and advanced delivery systems gain traction, subcutaneous administration is set to drive market growth in the forecast period, ensuring effective diabetes management.
Canada Diabetes Market Analysis by Region
Central Canada is projected to hold a substantial market share due to its dense population and well-established healthcare infrastructure. The provinces of Ontario and Quebec, which make up this region, account for a significant portion of the country's diabetes cases. Urbanisation and lifestyle-related factors contribute to the higher prevalence of Type II diabetes, driving demand for advanced treatments and management solutions. Central Canada benefits from robust research initiatives, healthcare funding, and partnerships between public and private sectors, which facilitate early diagnosis and access to innovative therapies. The region's focus on adopting digital health tools and cutting-edge treatments further strengthens its market leadership. With continued investments in healthcare innovation and increasing public awareness, Central Canada is well-positioned to sustain its dominance and drive overall market growth in the coming years.
Leading Players in the Canada Diabetes Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company
Founded in 1876 and headquartered in Indianapolis, Eli Lilly and Company is a global leader in diabetes care, renowned for its innovative treatments like Trulicity and Humalog. In December 2024, Eli Lilly Canada announced groundbreaking results from the SURMOUNT-5 Phase 3b clinical trial, showing tirzepatide achieved a 47% greater relative weight loss compared to Wegovy® (semaglutide), with an average 20.2% weight loss over 72 weeks. This superior efficacy highlights Eli Lilly’s commitment to addressing obesity, a key diabetes comorbidity, which will drive market growth by offering highly effective treatment options and strengthening its leadership in Canada’s healthcare sector.
AstraZeneca Plc
AstraZeneca, headquartered in Cambridge, UK, is a global biopharmaceutical leader focusing on innovative treatments across therapeutic areas, including cardiovascular, renal, and metabolic diseases. In August 2021, AstraZeneca Canada achieved a significant milestone with Health Canada’s approval of Forxiga® (dapagliflozin), an SGLT2 inhibitor. This therapy reduces the risk of kidney function decline, end-stage kidney disease, and cardiovascular or renal death in adults with chronic kidney disease. The approval, supported by the DAPA-CKD Phase III trial, highlights AstraZeneca's commitment to advancing patient care. This breakthrough strengthens its portfolio and significantly impacts Canada's diabetes market by addressing critical comorbidities, improving patient outcomes, and driving demand for advanced, multifaceted therapies.
Sanofi
Sanofi, a global healthcare leader headquartered in Paris, France, has a significant presence in the diabetes market, offering a diverse portfolio of insulin products, GLP-1 receptor agonists, and cutting-edge diabetes therapies. For instance, in November 2024, Sanofi made a strategic investment in Zucara Therapeutics Inc., participating in its USD 20 million Series B financing. This partnership includes an exclusive right of first negotiation for Sanofi, showcasing its commitment to innovation. By supporting Zucara’s development of ZT-01, a once-daily therapeutic to prevent hypoglycaemia, Sanofi aims to address unmet needs in diabetes care, enhancing its market influence and driving long-term growth through pioneering treatment solutions.
Merck & Co., Inc.
Founded in 1891 and headquartered in Kenilworth, New Jersey, it plays a notable role in Canada’s diabetes market. The company is known for its DPP-4 inhibitors, including Januvia (sitagliptin), which helps regulate blood sugar levels in type 2 diabetes patients. Merck is dedicated to advancing diabetes care through research, education initiatives, and partnerships. Its focus on innovative solutions highlights a commitment to improving the quality of life for those living with diabetes across Canada.
Other key players in the market include Novartis AG, Boehringer Ingelheim International GmbH, and Novo Nordisk A/S.
Key Questions Answered in the Canada Diabetes Market
Canada Diabetes Market Overview
Diabetes is a chronic disease characterized by the inability of the body to produce sufficient insulin or when the body cannot respond to the effects of insulin effectively, leading to high blood glucose levels. Type 2 diabetes is the most common type of diabetes where the body doesn’t make enough insulin or shows insulin resistance.
Canada Diabetes Market Growth Drivers
Rising Diabetes Cases to Drive Market Expansion
The growing prevalence of diabetes, fuelled by sedentary lifestyles and ageing populations, coupled with the high burden of diabetes-related complications, are key drivers shaping Canada’s diabetes market. A national analysis in 2024 reported 5.8 million Canadians living with diabetes, a figure expected to rise to over 7.3 million by 2034, representing 16% of the population. Additionally, diabetes contributes significantly to cardiovascular disease, kidney failure, and amputations. This alarming trend will amplify the demand for advanced diagnostic tools, innovative therapies, and public health initiatives, accelerating market growth throughout the forecast period.
Government Healthcare Initiatives to Boost Canada Diabetes Market Development
Expanding access to diabetes care through government support is a critical driver for market development. In February 2024, Canada introduced Bill C-64, the Pharmacare Act, covering diabetes medications and devices. Concurrently, the government announced a Device Fund to subsidise essential supplies, including insulin pumps and glucose monitoring devices. A USD 1 million grant was allocated in June 2023 to Diabetes Canada which further supports the strategic implementation of the national diabetes framework. These initiatives will enhance accessibility and affordability of care, driving the adoption of advanced treatment options and significantly contributing to market growth in the coming years.
Adoption of Innovative Therapies to Meet the Increasing Canada Diabetes Market Demand
Rising demand for convenient and patient-friendly therapies continues to drive innovation in diabetes treatment. In June 2024, Novo Nordisk introduced Awiqli® (insulin icodec), the world’s first once-weekly basal insulin, in Canada following Health Canada approval in March 2024. This groundbreaking therapy, designed to improve glycaemic control with reduced injection frequency, addresses adherence challenges in diabetes management. With Canada leading the global launch of Awiqli®, the treatment is expected to revolutionise insulin therapy standards. Its adoption will boost patient outcomes, foster technological advancements, and position Canada as a leader in diabetes care, driving significant market growth.
Canada Diabetes Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Prevalence of Type 2 Diabetes Fuels Market Development
Type 2 diabetes prevalence in Canada is increasing due to sedentary lifestyles, ageing populations, and unhealthy dietary patterns. As estimated by Diabetes Canada, the prevalence of diagnosed type I and type II diabetes is likely to increase by nearly 32% during 2024-2034. This surge is boosting demand for innovative treatment options, including combination therapies and novel drug classes. Efforts by public health organisations to enhance diabetes awareness and screening are contributing to early diagnoses and treatment adoption. Additionally, pharmaceutical companies are collaborating with healthcare providers to address gaps in care. This trend signifies robust market development as stakeholders focus on mitigating the disease burden and improving patient quality of life.
Growing Adoption of Digital Health Tools in Diabetes Management to Meet Increasing Canada Diabetes Market Demand
Digital health technologies, including mobile apps, continuous glucose monitoring (CGM) systems, and telemedicine, are becoming integral in diabetes care across Canada. These tools empower patients to monitor blood sugar levels in real-time and enable healthcare providers to offer personalised treatment plans remotely. With rising smartphone penetration and improved healthcare infrastructure, the market is witnessing increased investments in digital solutions. This trend highlights a shift towards technology-driven care, driven by patient demand for convenience and accuracy, alongside healthcare professionals' focus on enhanced outcomes.
Expanding Portfolio of Advanced Insulin Delivery Systems
The Canadian diabetes market is experiencing significant advancements in insulin delivery systems, including wearable insulin pumps and smart pens. These innovations improve patient compliance and ensure precise dosage administration. The growing awareness of diabetes complications and government efforts to subsidise innovative treatment devices are driving market growth. Manufacturers are also focusing on integrating AI and connectivity features to offer data-driven solutions. This trend underlines the evolving focus on convenience and efficiency in diabetes management, making insulin delivery more accessible and effective for patients across Canada.
Surge in Demand for Personalised Diabetes Treatments to Boost Canada Diabetes Market Value
The market is witnessing increased demand for personalised therapies tailored to individual needs. Advances in genetic research, artificial intelligence, and patient data analysis are enabling customised treatment plans, including specific drug combinations and lifestyle recommendations. This approach enhances treatment effectiveness and minimises side effects, making it a preferred choice for healthcare providers and patients alike. Pharmaceutical companies are investing in precision medicine to meet this growing demand. The shift towards personalised care signifies a transformative trend, reflecting patient-centric innovation and improved healthcare outcomes in diabetes management across Canada.
Canada Diabetes Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Diabetes Type
- Type I
- Type II
- Oral Anti-Diabetic Drugs
- Alpha-Glucosidase Inhibitor
- Biguanides
- Dopamine-2 Agonists
- DPP-4 Inhibitors
- Meglitinides
- SLGT2 Inhibitors
- Sulfonylureas
- Insulin
- Basal or Long-acting Insulin
- Insulin Glargine
- Bolus or Fast-acting Insulin
- Traditional Human Insulin
- Biosimilar Insulin
- Non-Insulin Injectable Drugs
- GLP-1 Receptor Agonists
- Amylin Analogue
- Combination Drugs
- Combination Insulin
- Oral Combination
- Oral
- Subcutaneous
- Intravenous
- Northern Canada
- British Columbia
- Alberta
- The Prairies
- Central Canada
- Atlantic Canada
Type II Diabetes to Lead the Diabetes Type Segment
Type II diabetes is expected a large market share based on diabetes type, driven by its growing prevalence due to sedentary lifestyles, unhealthy diets, and an ageing population. Its management requires a wide range of treatments, from oral medications to insulin therapies, creating substantial demand. Increased public awareness, early diagnosis programmes, and government healthcare initiatives further fuel growth. As per the analysis by Expert Market Research, the type 2 diabetes market is expected to grow at a CAGR of 8.4% during the forecast period of 2025-2034. Innovations in combination therapies and personalised treatments are poised to expand the segment's dominance in the forecast period, ensuring sustained market growth and improved patient outcomes.
Market Share Based on Drugs to Witness Substantial Growth in the Canada Diabetes Market
The oral anti-diabetic drugs segment is predicted to lead the market due to their convenience, cost-effectiveness, and extensive use in managing type 2 diabetes. Among these, DPP-4 inhibitors and SGLT2 inhibitors are experiencing significant growth due to their dual benefits in glucose control and cardiovascular health. Rising healthcare awareness and a shift towards minimally invasive options are market drivers. With continuous advancements in oral drug formulations and increasing adoption, this segment is expected to maintain its leadership and support future market expansion.
Canada Diabetes Market Share Based on Route of Administration to Hold a Significant Value
Subcutaneous administration leads the diabetes market in Canada due to its critical role in delivering insulin and non-insulin injectables like GLP-1 receptor agonists. Its efficiency in ensuring precise drug delivery and bioavailability makes it a preferred choice for patients and healthcare providers. Technological innovations in auto-injectors and insulin pumps further enhance its appeal. As personalised treatments and advanced delivery systems gain traction, subcutaneous administration is set to drive market growth in the forecast period, ensuring effective diabetes management.
Canada Diabetes Market Analysis by Region
Central Canada is projected to hold a substantial market share due to its dense population and well-established healthcare infrastructure. The provinces of Ontario and Quebec, which make up this region, account for a significant portion of the country's diabetes cases. Urbanisation and lifestyle-related factors contribute to the higher prevalence of Type II diabetes, driving demand for advanced treatments and management solutions. Central Canada benefits from robust research initiatives, healthcare funding, and partnerships between public and private sectors, which facilitate early diagnosis and access to innovative therapies. The region's focus on adopting digital health tools and cutting-edge treatments further strengthens its market leadership. With continued investments in healthcare innovation and increasing public awareness, Central Canada is well-positioned to sustain its dominance and drive overall market growth in the coming years.
Leading Players in the Canada Diabetes Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company
Founded in 1876 and headquartered in Indianapolis, Eli Lilly and Company is a global leader in diabetes care, renowned for its innovative treatments like Trulicity and Humalog. In December 2024, Eli Lilly Canada announced groundbreaking results from the SURMOUNT-5 Phase 3b clinical trial, showing tirzepatide achieved a 47% greater relative weight loss compared to Wegovy® (semaglutide), with an average 20.2% weight loss over 72 weeks. This superior efficacy highlights Eli Lilly’s commitment to addressing obesity, a key diabetes comorbidity, which will drive market growth by offering highly effective treatment options and strengthening its leadership in Canada’s healthcare sector.
AstraZeneca Plc
AstraZeneca, headquartered in Cambridge, UK, is a global biopharmaceutical leader focusing on innovative treatments across therapeutic areas, including cardiovascular, renal, and metabolic diseases. In August 2021, AstraZeneca Canada achieved a significant milestone with Health Canada’s approval of Forxiga® (dapagliflozin), an SGLT2 inhibitor. This therapy reduces the risk of kidney function decline, end-stage kidney disease, and cardiovascular or renal death in adults with chronic kidney disease. The approval, supported by the DAPA-CKD Phase III trial, highlights AstraZeneca's commitment to advancing patient care. This breakthrough strengthens its portfolio and significantly impacts Canada's diabetes market by addressing critical comorbidities, improving patient outcomes, and driving demand for advanced, multifaceted therapies.
Sanofi
Sanofi, a global healthcare leader headquartered in Paris, France, has a significant presence in the diabetes market, offering a diverse portfolio of insulin products, GLP-1 receptor agonists, and cutting-edge diabetes therapies. For instance, in November 2024, Sanofi made a strategic investment in Zucara Therapeutics Inc., participating in its USD 20 million Series B financing. This partnership includes an exclusive right of first negotiation for Sanofi, showcasing its commitment to innovation. By supporting Zucara’s development of ZT-01, a once-daily therapeutic to prevent hypoglycaemia, Sanofi aims to address unmet needs in diabetes care, enhancing its market influence and driving long-term growth through pioneering treatment solutions.
Merck & Co., Inc.
Founded in 1891 and headquartered in Kenilworth, New Jersey, it plays a notable role in Canada’s diabetes market. The company is known for its DPP-4 inhibitors, including Januvia (sitagliptin), which helps regulate blood sugar levels in type 2 diabetes patients. Merck is dedicated to advancing diabetes care through research, education initiatives, and partnerships. Its focus on innovative solutions highlights a commitment to improving the quality of life for those living with diabetes across Canada.
Other key players in the market include Novartis AG, Boehringer Ingelheim International GmbH, and Novo Nordisk A/S.
Key Questions Answered in the Canada Diabetes Market
- What was the Canada diabetes market value in 2024?
- What is the Canada diabetes market forecast outlook for 2025-2034?
- What is market segmentation based on diabetes type?
- What is market segmentation based on drugs?
- What is market segmentation based on the route of administration?
- What are the major factors aiding the Canada diabetes market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Canada diabetes market trends?
- Which diabetes type will lead the market segment?
- Which drugs will lead the market segment?
- Which route of administration will lead the market segment?
- Who are the key players involved in the Canada diabetes market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Diabetes Market Overview
- 3.1 North America Diabetes Market
- 3.1.1 North America Diabetes Market Historical Value (2018-2024)
- 3.1.2 North America Diabetes Market Forecast Value (2025-2034)
- 3.2 Canada Diabetes Market
- 3.2.1 Canada Diabetes Market Historical Value (2018-2024)
- 3.2.2 Canada Diabetes Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Canada Diabetes Market: Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Canada Diabetes Market - Epidemiology Scenario and Forecast
- 8 Canada Diabetes Market Landscape*
- 8.1 Canada Diabetes Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Canada Diabetes Market: Product Landscape
- 8.2.1 Analysis by Drugs
- 8.2.2 Analysis by Route of Administration
- 9 Canada Diabetes Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Canada Diabetes Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Canada Diabetes Market Segmentation (218-2034)
- 12.1 Canada Diabetes Market (2018-2034) by Diabetes Type
- 12.1.1 Market Overview
- 12.1.2 Type I
- 12.1.3 Type II
- 12.2 Canada Diabetes Market (2018-2034) by Drugs
- 12.2.1 Market Overview
- 12.2.2 Oral Anti-Diabetic Drugs
- 12.2.2.1 Alpha-Glucosidase Inhibitor
- 12.2.2.2 Biguanides
- 12.2.2.3 Dopamine-2 Agonists
- 12.2.2.4 DPP-4 Inhibitors
- 12.2.2.5 Meglitinides
- 12.2.2.6 SLGT2 Inhibitors
- 12.2.2.7 Sulfonylureas
- 12.2.3 Insulin
- 12.2.3.1 Basal or Long-acting Insulin
- 12.2.3.2 Insulin Glargine
- 12.2.3.3 Bolus or Fast-acting Insulin
- 12.2.3.4 Traditional Human Insulin
- 12.2.3.5 Biosimilar Insulin
- 12.2.4 Non-Insulin Injectable Drugs
- 12.2.4.1 GLP-1 Receptor Agonists
- 12.2.4.2 Amylin Analogue
- 12.2.5 Combination Drugs
- 12.2.5.1 Combination Insulin
- 12.2.5.2 Oral Combination
- 12.3 Canada Diabetes Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Subcutaneous
- 12.3.4 Intravenous
- 12.4 Canada Diabetes Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 Northern Canada
- 12.4.3 British Columbia
- 12.4.4 Alberta
- 12.4.5 The Prairies
- 12.4.6 Central Canada
- 12.4.7 Atlantic Canada
- 13 Northern Canada Diabetes Market Segmentation (218-2034)
- 13.1 Northern Canada Diabetes Market Historical Value (2018-2024)
- 13.2 Northern Canada Diabetes Market Forecast Value (2025-2034)
- 13.3 Northern Canada Diabetes Market (2018-2034) by Diabetes Type
- 13.3.1 Market Overview
- 13.3.2 Type I
- 13.3.3 Type II
- 13.4 Northern Canada Diabetes Market (2018-2034) by Drugs
- 13.4.1 Market Overview
- 13.4.2 Oral Anti-Diabetic Drugs
- 13.4.3 Insulin
- 13.4.4 Non-Insulin Injectable Drugs
- 13.4.5 Combination Drugs
- 14 British Columbia Diabetes Market Segmentation (218-2034)
- 14.1 British Columbia Diabetes Market Historical Value (2018-2024)
- 14.2 British Columbia Diabetes Market Forecast Value (2025-2034)
- 14.3 British Columbia Diabetes Market (2018-2034) by Diabetes Type
- 14.3.1 Market Overview
- 14.3.2 Type I
- 14.3.3 Type II
- 14.4 British Columbia Diabetes Market (2018-2034) by Drugs
- 14.4.1 Market Overview
- 14.4.2 Oral Anti-Diabetic Drugs
- 14.4.3 Insulin
- 14.4.4 Non-Insulin Injectable Drugs
- 14.4.5 Combination Drugs
- 15 Alberta Diabetes Market Segmentation (218-2034)
- 15.1 Alberta Diabetes Market Historical Value (2018-2024)
- 15.2 Alberta Diabetes Market Forecast Value (2025-2034)
- 15.3 Alberta Diabetes Market (2018-2034) by Diabetes Type
- 15.3.1 Market Overview
- 15.3.2 Type I
- 15.3.3 Type II
- 15.4 Alberta Diabetes Market (2018-2034) by Drugs
- 15.4.1 Market Overview
- 15.4.2 Oral Anti-Diabetic Drugs
- 15.4.3 Insulin
- 15.4.4 Non-Insulin Injectable Drugs
- 15.4.5 Combination Drugs
- 16 The Prairies Diabetes Market Segmentation (218-2034)
- 16.1 The Prairies Diabetes Market Historical Value (2018-2024)
- 16.2 The Prairies Diabetes Market Forecast Value (2025-2034)
- 16.3 The Prairies Diabetes Market (2018-2034) by Diabetes Type
- 16.3.1 Market Overview
- 16.3.2 Type I
- 16.3.3 Type II
- 16.4 The Prairies Diabetes Market (2018-2034) by Drugs
- 16.4.1 Market Overview
- 16.4.2 Oral Anti-Diabetic Drugs
- 16.4.3 Insulin
- 16.4.4 Non-Insulin Injectable Drugs
- 16.4.5 Combination Drugs
- 17 Central Canada Diabetes Market Segmentation (218-2034)
- 17.1 Central Canada Diabetes Market Historical Value (2018-2024)
- 17.2 Central Canada Diabetes Market Forecast Value (2025-2034)
- 17.3 Central Canada Diabetes Market (2018-2034) by Diabetes Type
- 17.3.1 Market Overview
- 17.3.2 Type I
- 17.3.3 Type II
- 17.4 Central Canada Diabetes Market (2018-2034) by Drugs
- 17.4.1 Market Overview
- 17.4.2 Oral Anti-Diabetic Drugs
- 17.4.3 Insulin
- 17.4.4 Non-Insulin Injectable Drugs
- 17.4.5 Combination Drugs
- 18 Atlantic Canada Diabetes Market Segmentation (218-2034)
- 18.1 Atlantic Canada Diabetes Market Historical Value (2018-2024)
- 18.2 Atlantic Canada Diabetes Market Forecast Value (2025-2034)
- 18.3 Atlantic Canada Diabetes Market (2018-2034) by Diabetes Type
- 18.3.1 Market Overview
- 18.3.2 Type I
- 18.3.3 Type II
- 18.4 Atlantic Canada Diabetes Market (2018-2034) by Drugs
- 18.4.1 Market Overview
- 18.4.2 Oral Anti-Diabetic Drugs
- 18.4.3 Insulin
- 18.4.4 Non-Insulin Injectable Drugs
- 18.4.5 Combination Drugs
- 19 Regulatory Framework
- 20 Patent Analysis
- 20.1 Analysis by Type of Patent
- 20.2 Analysis by Publication Year
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Patent Age
- 20.5 Analysis by CPC Analysis
- 20.6 Analysis by Patent Valuation
- 20.7 Analysis by Key Players
- 21 Clinical Trials Analysis
- 21.1 Analysis by Trial Registration Year
- 21.2 Analysis by Trial Status
- 21.3 Analysis by Trial Phase
- 21.4 Analysis by Therapeutic Area
- 21.5 Analysis by Geography
- 22 Grant Analysis
- 22.1 Analysis by Year
- 22.2 Analysis by Amount Awarded
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Grant Product
- 22.5 Analysis by Funding Institute
- 22.6 Analysis by Departments
- 22.7 Analysis by Recipient Organization
- 23 Funding and Investment Analysis
- 23.1 Analysis by Funding Instances
- 23.2 Analysis by Type of Funding
- 23.3 Analysis by Funding Amount
- 23.4 Analysis by Leading Players
- 23.5 Analysis by Leading Investors
- 23.6 Analysis by Geography
- 24 Strategic Initiatives
- 24.1 Analysis by Partnership Instances
- 24.2 Analysis by Type of Partnership and Collaborations
- 24.3 Analysis by Joint Ventures
- 24.4 Analysis by Leading Players
- 24.5 Analysis by Geography
- 25 Supplier Landscape
- 25.1 Market Share Analysis, By Region (Top 5 Companies)
- 25.2 Eli Lilly and Company
- 25.2.1 Financial Analysis
- 25.2.2 Product Portfolio
- 25.2.3 Demographic Reach and Achievements
- 25.2.4 Company News and Developments
- 25.2.5 Certifications
- 25.3 AstraZeneca Plc.
- 25.3.1 Financial Analysis
- 25.3.2 Product Portfolio
- 25.3.3 Demographic Reach and Achievements
- 25.3.4 Company News and Developments
- 25.3.5 Certifications
- 25.4 Sanofi
- 25.4.1 Financial Analysis
- 25.4.2 Product Portfolio
- 25.4.3 Demographic Reach and Achievements
- 25.4.4 Company News and Developments
- 25.4.5 Certifications
- 25.5 Merck & Co., Inc.
- 25.5.1 Financial Analysis
- 25.5.2 Product Portfolio
- 25.5.3 Demographic Reach and Achievements
- 25.5.4 Company News and Developments
- 25.5.5 Certifications
- 25.6 Novartis AG
- 25.6.1 Financial Analysis
- 25.6.2 Product Portfolio
- 25.6.3 Demographic Reach and Achievements
- 25.6.4 Company News and Developments
- 25.6.5 Certifications
- 25.7 Boehringer Ingelheim International GmbH
- 25.7.1 Financial Analysis
- 25.7.2 Product Portfolio
- 25.7.3 Demographic Reach and Achievements
- 25.7.4 Company News and Developments
- 25.7.5 Certifications
- 25.8 Novo Nordisk A/S
- 25.8.1 Financial Analysis
- 25.8.2 Product Portfolio
- 25.8.3 Demographic Reach and Achievements
- 25.8.4 Company News and Developments
- 25.8.5 Certifications
- 26 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
